715-46-8

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dichloro-5-nitro-2-(trifluoromethyl)pyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals due to its potent biological activities. It plays a crucial role in the development of new drugs for the treatment of diseases such as cancer and bacterial infections.
Used in Agrochemical Industry:
In the agrochemical industry, 4,6-Dichloro-5-nitro-2-(trifluoromethyl)pyrimidine is utilized as an intermediate for the production of fungicides and herbicides. Its potent biological activities make it an effective component in controlling the growth of unwanted plants and fungi, thereby protecting crops and enhancing agricultural productivity.
Used in Organic Synthesis:
4,6-Dichloro-5-nitro-2-(trifluoromethyl)pyrimidine is a valuable building block in organic synthesis. Its unique structure and functional groups allow for further chemical modifications, enabling the synthesis of a wide range of compounds with diverse applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Overall, 4,6-Dichloro-5-nitro-2-(trifluoromethyl)pyrimidine is a versatile and important chemical compound with significant applications in both the pharmaceutical and agricultural industries, as well as in organic synthesis. Its potent biological activities and ability to serve as a key intermediate in the synthesis of various compounds make it a valuable asset in the development of new drugs, agrochemicals, and other products.

InChI:InChI=1/C5Cl2F3N3O2/c6-2-1(13(14)15)3(7)12-4(11-2)5(8,9)10

Upstream product

• 652-62-0 5-nitro-2-trifluoromethyl-1H-pyrimidine-4,6-dione 
• 672-47-9 2-trifluoromethyl-4,6-dihydroxypyrimidine 
• 917895-54-6 6-chloro-5-nitro-2-(trifluoromethyl)pyrimidin-4-ol 

Downstream Products

• 53039-37-5 (6-chloro-5-nitro-2-trifluoromethyl-pyrimidin-4-yl)-ethyl-amine 
• 2344-17-4 4,6-dichloro-2-trifluoromethyl-pyrimidin-5-ylamine 
• 1305117-36-5 N₄-{[(2S)-4-Benzylmorpholin-2-yl]methyl}-6-chloro-2-(trifluoromethyl)pyrimidine-4,5-diamine 
• 1305117-37-6 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-7-chloro-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1305115-74-5 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 
• 1305115-80-3 PF-04957325 
• 1397685-89-0 C₁₆H₂₁F₃N₆O 
• 1397685-90-3 C₁₈H₁₉F₃N₆O₂ 
• 1397685-95-8 C₁₈H₁₉F₃N₆O 
• 1397685-96-9 C₁₈H₁₈F₄N₆O 
• 1397686-01-9 C₁₈H₁₉F₃N₆O₂ 

Relevant academic research and scientific papers

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.

Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.

SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS

Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.